التفاصيل البيبلوغرافية
| العنوان: |
Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's disease |
| المؤلفون: |
Guido Straten, Christoph Laske, Thomas Gasser, Hans Basun, Thomas Leyhe, Ralf Saur, Peter Annas |
| المصدر: |
Current Alzheimer research 8(8), 853-859 (2011). doi:10.2174/156720511798192754 |
| بيانات النشر: |
Bentham Science Publ. Ltd., 2011. |
| سنة النشر: |
2011 |
| مصطلحات موضوعية: |
Male, Neurology, Lithium (medication), pharmacology [Lithium Compounds], Neuropsychological Tests, Cerebrospinal fluid, Neurotrophic factors, Antimanic Agents, Glial cell line-derived neurotrophic factor, drug therapy [Alzheimer Disease], pharmacology [Sulfates], cerebrospinal fluid [Glial Cell Line-Derived Neurotrophic Factor], Single-Blind Method, Aged, 80 and over, biology, Sulfates, Middle Aged, therapeutic use [Neuroprotective Agents], cerebrospinal fluid [Alzheimer Disease], cerebrospinal fluid [Cognitive Dysfunction], Neuroprotective Agents, Lithium Compounds, Female, medicine.symptom, Neurotrophin, medicine.drug, drug therapy [Cognitive Dysfunction], medicine.medical_specialty, lithium sulfate, blood [Glial Cell Line-Derived Neurotrophic Factor], Placebo, blood [Alzheimer Disease], Alzheimer Disease, Internal medicine, medicine, Humans, Cognitive Dysfunction, ddc:610, Glial Cell Line-Derived Neurotrophic Factor, Aged, business.industry, pharmacology [Neuroprotective Agents], Endocrinology, Mechanism of action, therapeutic use [Antimanic Agents], blood [Cognitive Dysfunction], biology.protein, Neurology (clinical), business, pharmacology [Antimanic Agents] |
| الوصف: |
Preclinical and clinical studies gave evidence that lithium could be useful in the treatment of Alzheimer's disease (AD). One possible mechanism of action might be the induction of neurotrophins. Recently, we found a significant increase of brain-derived neurotrophic factor (BDNF) serum levels in AD patients treated with lithium and a significant decrease of ADAS Cog sum scores in comparison to placebo-treated patients. In another previous study we have shown that glial cell line-derived neurotrophic factor (GDNF) levels in CSF of patients with early AD are increased most probably due to an upregulated expression in CNS as an adaptive process of the impaired brain to enhance neurotrophic support at least in early stages of disease. Here we assessed the influence of a lithium treatment on GDNF serum and cerebrospinal fluid (CSF) concentrations in a subset of a greater sample recruited for a randomized, single-blinded, placebo-controlled, parallel-group multicenter 10-week study, investigating the efficacy of lithium treatment in AD patients. We found a significant negative correlation of lithium concentration in serum with GDNF concentration in CSF at the end of treatment (r = -0.585, p = 0.036) and with the difference of GDNF concentration in CSF before and after treatment (r = - 0.755, p = 0.003). However, we could not show a difference in GDNF concentrations between the patients after the treatment with lithium or placebo (serum, mean ± standard deviation: 434.3 ± 117.9 pg/ml versus 543.8 ± 250.0 pg/ml, p = 0.178; CSF, 62.3 ± 37.4 pg/ml versus 72.8 ± 43.9 pg/ml, p = 0.511). The findings of the present investigation indicated that beneficial effects of the lithium treatment might reduce the necessity of enhanced GDNF expression in the CNS in early AD. |
| اللغة: |
English |
| DOI: |
10.2174/156720511798192754 |
| URL الوصول: |
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a9e3442b5d316f658d460ec8335954d |
| Rights: |
CLOSED |
| رقم الانضمام: |
edsair.doi.dedup.....1a9e3442b5d316f658d460ec8335954d |
| قاعدة البيانات: |
OpenAIRE |